Next Article in Journal
PTEN Protein Loss and Loss-of-Function Mutations in Gastric Cancers: The Relationship with Microsatellite Instability, EBV, HER2, and PD-L1 Expression
Next Article in Special Issue
Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI–IM–MS/MS Assay
Previous Article in Journal
Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts
Previous Article in Special Issue
Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
Journals
Cancers
Volume 12
Issue 7
10.3390/cancers12071725
cancers-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Article

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo

by
Nizar Serhan
1,†,
Pierre-Luc Mouchel
2,3,†,
Philippe de Medina
1,
Gregory Segala
1,
Aurélie Mougel
1,
Estelle Saland
2,
Arnaud Rives
4,5,
Antonin Lamaziere
6,
Gaëtan Despres
6,
Jean-Emmanuel Sarry
2,
Clément Larrue
2,
François Vergez
3,
Laetitia Largeaud
3,
Michel Record
1,
Christian Récher
2,3,*,
Sandrine Silvente-Poirot
1,* and
Marc Poirot
1,*
1
Unité Mixte de Recherche (UMR) 1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France
2
Cancer Research Center of Toulouse (CRCT), Unité Mixte de Recherche (UMR) 1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 Centre national de la recherche scientifique (CNRS), Team Drug Resistance and Oncometabolism in Acute Myeloid Leukemia, 31037 Toulouse, France
3
Service d’Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Université de Toulouse, 31400 Toulouse, France
4
AFFICHEM, 31400 Toulouse, France
5
Dendrogenix, 4000 Liège, Belgium
6
Laboratory of Mass Spectrometry, Institut National de la Santé et de la Recherche Médicale (INSERM) ERL 1157, Centre national de la recherche scientifique (CNRS) Unité Mixte de Recherche (UMR) 7203 LBM, Sorbonne Universités-UPMC, CHU Saint-Antoine, 75012 Paris, France
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2020, 12(7), 1725; https://doi.org/10.3390/cancers12071725
Received: 21 May 2020 / Revised: 19 June 2020 / Accepted: 25 June 2020 / Published: 29 June 2020
(This article belongs to the Special Issue Targeted Cancer Therapy)
View Full-Text Download PDF
Browse Figures
Review Reports

Abstract

Dendrogenin A (DDA) is a mammalian cholesterol metabolite that displays potent antitumor properties on acute myeloid leukemia (AML). DDA triggers lethal autophagy in cancer cells through a biased activation of the oxysterol receptor LXRβ, and the inhibition of a sterol isomerase. We hypothesize that DDA could potentiate the activity of an anticancer drug acting through a different molecular mechanism, and conducted in vitro and in vivo combination tests on AML cell lines and patient primary tumors. We report here results from tests combining DDA with antimetabolite cytarabine (Ara-C), one of the main drugs used for AML treatment worldwide. We demonstrated that DDA potentiated and sensitized AML cells, including primary patient samples, to Ara-C in vitro and in vivo. Mechanistic studies revealed that this sensitization was LXRβ-dependent and was due to the activation of lethal autophagy. This study demonstrates a positive in vitro and in vivo interaction between DDA and Ara-C, and supports the clinical evaluation of DDA in combination with Ara-C for the treatment of AML. View Full-Text
Keywords: Acute myeloid leukemia; Dendrogenin A; tumor suppressor; cholesterol metabolism; synergy; primary cancer cells Acute myeloid leukemia; Dendrogenin A; tumor suppressor; cholesterol metabolism; synergy; primary cancer cells
►▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

SciFeed

Share and Cite

MDPI and ACS Style

Serhan, N.; Mouchel, P.-L.; de Medina, P.; Segala, G.; Mougel, A.; Saland, E.; Rives, A.; Lamaziere, A.; Despres, G.; Sarry, J.-E.; Larrue, C.; Vergez, F.; Largeaud, L.; Record, M.; Récher, C.; Silvente-Poirot, S.; Poirot, M. Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. Cancers 2020, 12, 1725. https://doi.org/10.3390/cancers12071725

AMA Style

Serhan N, Mouchel P-L, de Medina P, Segala G, Mougel A, Saland E, Rives A, Lamaziere A, Despres G, Sarry J-E, Larrue C, Vergez F, Largeaud L, Record M, Récher C, Silvente-Poirot S, Poirot M. Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. Cancers. 2020; 12(7):1725. https://doi.org/10.3390/cancers12071725

Chicago/Turabian Style

Serhan, Nizar, Pierre-Luc Mouchel, Philippe de Medina, Gregory Segala, Aurélie Mougel, Estelle Saland, Arnaud Rives, Antonin Lamaziere, Gaëtan Despres, Jean-Emmanuel Sarry, Clément Larrue, François Vergez, Laetitia Largeaud, Michel Record, Christian Récher, Sandrine Silvente-Poirot, and Marc Poirot. 2020. "Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo" Cancers 12, no. 7: 1725. https://doi.org/10.3390/cancers12071725

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Back to TopTop